Since E2 is the principal inducer of both VEGF and T-Regs, it is conceivable that by decreasing E2 with a luteneizing hormone-releasing hormone (LH-RH) analogue as part of the adjuvant therapy, we may decrease the levels of VEGF and T-Regs and thus improve the clinical outcome of premenopausal patients with BC. Here, VEGFA is linked to breast cancer.